M. Granadillo

发表

A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.

M. G. Vallespí, Y. Soria, I. Torréns, 2011, Vaccine.

The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

M. G. Vallespí, Y. Soria, I. Torréns, 2016 .

Human papillomavirus vaccines: current status and perspectives

I. Torréns, M. Granadillo, 2008 .

Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate.

A. Blanco, D. Urquiza, I. Torréns, 2019, Vaccine.

Immunization with Neisseria meningitidis outer membrane vesicles prevents bacteremia in neonatal mice.

R. Pajon, Y. Soria, M. Granadillo, 2006, Vaccine.

Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen

L. Betancourt, V. Besada, A. Musacchio, 2013, SpringerPlus.

Expression , purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E 7 antigen

L. Betancourt, V. Besada, A. Musacchio, 2013 .

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine ( CIGB-228 ) inWomen with High-Grade Cervical Intraepithelial Neoplasia : First-inHuman , Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2014 .

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

P. López-Saura, A. Ferrer, I. Torréns, 2011, ISRN obstetrics and gynecology.

LALF32‐51‐E7, a HPV‐16 therapeutic vaccine candidate, forms protein body‐like structures when expressed in Nicotiana benthamiana leaves

E. Arcalis, E. Rybicki, I. Hitzeroth, 2017, Plant biotechnology journal.

Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana

E. Rybicki, I. Hitzeroth, I. Torréns, 2017, PloS one.

Identification of a novel antitumor peptide based on the screening of an Ala‐library derived from the LALF32–51 region

O. Mendoza, G. Guillén, H. Garay, 2010, Journal of peptide science : an official publication of the European Peptide Society.

A NOVEL STRATEGY TO IMPROVE ANTIGEN PRESENTATION FOR ACTIVE IMMUNOTHERAPY IN CANCER. FUSION OF THE HUMAN PAPILLOMAVIRUS TYPE 16 E7 ANTIGEN TO A CELL PENETRATING PEPTIDE

O. Mendoza, V. Falcón, M. Granadillo, 2014 .

LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs

L. Aldana, A. Blanco, I. Torréns, 2017, Clinical & Experimental Metastasis.

Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16

I. Torréns, M. Granadillo, A. Batte, 2018, Journal of Cellular Immunotherapy.